Williams H, Powell IJ. Epidemiology, pathology, and genetics of prostate cancer among African Americans compared with other ethnicities. Methods Mol Biol. 2009;472:439–53.
Krimphove MJ, Cole AP, Fletcher SA, Harmouch SS, Berg S, Lipsitz SR, et al. Evaluation of the contribution of demographics, access to health care, treatment, and tumor characteristics to racial differences in survival of advanced prostate cancer. Prostate Cancer Prostatic Dis. 2019;22:125–36.
Wen W, Luckenbaugh AN, Bayley CE, Penson DF, Shu XO. Racial disparities in mortality for patients with prostate cancer after radical prostatectomy. Cancer. 2021;127:1517–28.
Dickey SL, Ogunsanya ME. Quality of life among black prostate cancer survivors: an integrative review. Am J Mens Health. 2018;12:1648–64.
Article PubMed PubMed Central Google Scholar
Moses KA, Paciorek AT, Penson DF, Carroll PR, Master VA. Impact of ethnicity on primary treatment choice and mortality in men with prostate cancer: data from CaPSURE. J Clin Oncol J Am Soc Clin Oncol. 2010;28:1069–74.
Sayyid RK, Klotz L, Benton JZ, Ma M, Woodruff P, Satkunasivam R, et al. Active surveillance in favorable intermediate-risk prostate cancer patients: predictors of deferred intervention and treatment choice. J Assoc Urol Can. 2021;16:E7–E14.
Orom H, Biddle C, Underwood W, Homish GG, Olsson CA. Racial or ethnic and socioeconomic disparities in prostate cancer survivors’ prostate-specific quality of life. Urology. 2018;112:132–7.
Lubeck DP, Kim H, Grossfeld G, Ray P, Penson DF, Flanders SC, et al. Health related quality of life differences between black and white men with prostate cancer: data from the cancer of the prostate strategic urologic research endeavor. J Urol. 2001;166:2281–5.
Article CAS PubMed Google Scholar
Brassell SA, Dobi A, Petrovics G, Srivastava S, McLeod D. The Center for Prostate Disease Research (CPDR): a multidisciplinary approach to translational research. Urol Oncol. 2009;27:562–9.
Odeo S, Degu A. Factors affecting health-related quality of life among prostate cancer patients: a systematic review. J Oncol Pharm Pract. 2020;26:1997–2010.
Lev EL, Eller LS, Gejerman G, Kolassa J, Colella J, Pezzino J, et al. Quality of life of men treated for localized prostate cancer: outcomes at 6 and 12 months. Support Care Cancer J Multinatl Assoc Support Care Cancer. 2009;17:509–17.
Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology. 2000;56:899–905.
Article CAS PubMed Google Scholar
Ware JE. SF-36 health survey update. Spine. 2000;25:3130–9.
Washington SL, Jeong CW, Lonergan PE, Herlemann A, Gomez SL, Carroll PR, et al. Regional variation in active surveillance for low-risk prostate cancer in the US. JAMA Netw Open. 2020;3:e2031349.
Article PubMed PubMed Central Google Scholar
Agrawal V, Ma X, Hu JC, Barbieri CE, Nagar H. Active surveillance for men with intermediate risk prostate cancer. J Urol. 2021;205:115–21.
Parikh RB, Robinson KW, Chhatre S, Medvedeva E, Cashy JP, Veera S, et al. Comparison by race of conservative management for low-risk and intermediate-risk prostate cancers in veterans from 2004 to 2018. JAMA Netw Open. 2020;3:e2018318.
Article PubMed PubMed Central Google Scholar
Shen X, Pettaway CA, Chen RC. Active surveillance for Black men with low-risk prostate cancer. JAMA. 2020;324:1733–4.
Mahal BA, Berman RA, Taplin ME, Huang FW. Prostate cancer–specific mortality across Gleason scores in Black vs Nonblack Men. JAMA. 2018;320:2479–81.
Schenk JM, Newcomb LF, Zheng Y, Faino AV, Zhu K, Nyame YA, et al. African American race is not associated with risk of reclassification during active surveillance: results from the canary prostate cancer active surveillance study. J Urol. 2020;203:727–33.
Deka R, Courtney PT, Parsons JK, Nelson TJ, Nalawade V, Luterstein E, et al. Association between African American race and clinical outcomes in men treated for low-risk prostate cancer with active surveillance. JAMA. 2020;324:1747–54.
Article PubMed PubMed Central Google Scholar
Butler S, Muralidhar V, Chavez J, Fullerton Z, Mahal A, Nezolosky M, et al. Active surveillance for low-risk prostate cancer in Black oatients. N Engl J Med [Internet]. 2019;380. https://pubmed.ncbi.nlm.nih.gov/31116925/. Accessed 19 Aug 2022.
DeWitt-Foy ME, Gam K, Modlin C, Kim SP, Abouassaly R. Race, decisional regret and prostate cancer beliefs: identifying targets to reduce racial disparities in prostate cancer. J Urol. 2021;205:426–33.
Shah C, Jones PM, Wallace M, Kestin LL, Ghilezan M, Fakhouri M, et al. Differences in disease presentation, treatment outcomes, and toxicities in African American patients treated with radiation therapy for prostate cancer. Am J Clin Oncol. 2012;35:566–71.
Michalski JM, Yan Y, Watkins-Bruner D, Bosch WR, Winter K, Galvin JM, et al. Preliminary toxicity analysis of 3-dimensional conformal radiation therapy versus intensity modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group 0126 prostate cancer trial. Int J Radiat Oncol Biol Phys. 2013;87:932–8.
McKay RR, Sarkar RR, Kumar A, Einck JP, Garraway IP, Lynch JA, et al. Outcomes of Black men with prostate cancer treated with radiation therapy in the Veterans Health Administration. Cancer. 2021;127:403–11.
Article CAS PubMed Google Scholar
Kodiyan J, Ashamalla M, Guirguis A, Ashamalla H. Race does not affect survival in patients with prostate cancer treated with radiation therapy. Anticancer Res. 2020;40:3307–14.
Article CAS PubMed Google Scholar
Gordon BBE, Basak R, Carpenter WR, Usinger D, Godley PA, Chen RC. Factors influencing prostate cancer treatment decisions for African American and white men. Cancer. 2019;125:1693–700.
Jenkins R, Schover LR, Fouladi RT, Warneke C, Neese L, Klein EA, et al. Sexuality and health-related quality of life after prostate cancer in African-American and white men treated for localized disease. J Sex Marital Ther. 2004;30:79–93.
Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358:1250–61.
Article CAS PubMed Google Scholar
Johnson TK, Gilliland FD, Hoffman RM, Deapen D, Penson DF, Stanford JL, et al. Racial/ethnic differences in functional outcomes in the 5 years after diagnosis of localized prostate cancer. J Clin Oncol J Am Soc Clin Oncol. 2004;22:4193–201.
Kimura M, Bañez LL, Schroeck FR, Gerber L, Qi J, Satoh T, et al. Factors predicting early and late phase decline of sexual health-related quality of life following radical prostatectomy. J Sex Med. 2011;8:2935–43.
Jayadevappa R, Johnson JC, Chhatre S, Wein AJ, Malkowicz SB. Ethnic variation in return to baseline values of patient-reported outcomes in older prostate cancer patients. Cancer. 2007;109:2229–38.
DeCastro GJ, Jayram G, Razmaria A, Shalhav A, Zagaja GP. Functional outcomes in African-Americans after robot-assisted radical prostatectomy. J Endourol. 2012;26:1013–9.
Tyson MD, Alvarez J, Koyama T, Hoffman KE, Resnick MJ, Wu XC, et al. Racial variation in patient-reported outcomes following treatment for localized prostate cancer: results from the CEASAR study. Eur Urol. 2017;72:307–14.
Burnett AL. Racial disparities in sexual dysfunction outcomes after prostate cancer treatment: myth or reality? J Racial Ethn Health Disparities. 2016;3:154–9.
留言 (0)